A review of Pharmacological Agents Used to Treat COVID-19 During the Pandemic

Covid 19 Pandemisi Sırasında Kullanılan Farmakolojik Ajanların Gözden Geçirilmesi

Fikriye Yasemin ÖZATİK

ÖZ


Anahtar Kelimeler: COVID-19; ilaç; farmakodinamik; farmakokinetik

ABSTRACT

A number of pneumonia cases have been reported in China since December 2019. After a series of researches, the World Health Organization named this disease caused by 2019-nCoV on 11 February 2020 as coronavirus disease (COVID-19). COVID-19 is a global pandemic. The aim of this review was to evaluate the pharmacokinetics and pharmacodynamics of the drugs used in COVID-19 pandemic

Evidence for efficacy of the drugs used in the COVID-19 pandemic is not yet clear. Further studies and information are needed on these drugs.

Key Words: COVID-19; drug, pharmacodynamics; pharmacokinetics

Received: 05.10.2020; Accepted: 03.01.2021

1 Kutahya Health Sciences University, Faculty of Medicine, Department of Pharmacology, Kutahya, Turkey.
Corresponding Author: Assoc. Prof. Dr. Fikriye Yasemin ÖZATİK, Kutahya Health Sciences University, Faculty of Medicine, Department of Pharmacology, Kutahya, Turkey. e-mail: fyozatik@hotmail.com

INTRODUCTION

In December 2019, a group of patients were identified to have pneumonia with unknown cause in Wuhan city, State of Hubei in China. Interestingly, all the patients had visited the Huanan Seafood Wholesale Market and shopped there. In December, Chinese Disease Control and Prevention Center and Wuhan city health authorities reported a novel pneumonia epidemic. The Chinese Disease Control and Prevention Center researched samples taken from the respiratory tracts of patients and identified a novel coronavirus. This coronavirus was later named as "Severe acute respiratory syndrome coronavirus-2". The World Health Organization (WHO) named this virus as coronavirus disease-2019 (COVID-19) as it emerged in 2019. Later, this virus spread throughout China and was identified in 114 countries in the next three months and caused more than 4000 deaths. It still continues to spread. Currently, the mortality rate is rapidly rising worldwide. COVID-19 caused great fear all over the world. Almost every country in the world has begun taking emergency measures. COVID-19 is a highly contagious disease with a rather poor prognosis and can lead to many deaths.

There are some medications used in the treatment of COVID-19. However, the COVID-19 pandemic is spreading rapidly and clinical trials of drugs that affect this virus and its symptoms are still ongoing. It is crucial for clinical research to recognize the pharmacokinetic and pharmacodynamics of drugs frequently used in the COVID-19 pandemic. This review aims to assess the COVID-19 treatment choices in terms of pharmacodynamics and pharmacokinetics.

MATERIALS and METHOD

Articles written only in English related to COVID-19 treatment protocols up to 1 June 2020 were screened and investigated on PubMed. Our key words were COVID-19, coronavirus, chloroquine, hydroxychloroquine, remdesivir, favipiravir, lopinavir, ritonavir, oseltamivir, nitazoxanide, nelfinavir, tocilizumab, plasma, immunoglobulins, corticosteroids, and azithromycin. Below the pharmacological activity and published clinical and preclinical experiences related to some medications researched for COVID-19 are reviewed.

RESULTS

Some Medications Used For Coronavirus

Chloroquine-Hydroxychloroquine

Chloroquine and hydroxychloroquine are used as antimalarial medication in addition to being used against a range of RNA viruses including Zika virus, Chikungunya virus, SARS-CoV and MERS. They are aminoquinoline class medications with proven efficacy against these viruses. The most accepted mechanism for chloroquine is inhibition of β hematin formation in the digestive vacuoles of the malaria parasite. Additionally, the effect mechanisms of chloroquine are still debated. It is thought that effects are due to changing the digestive food vacuole pH and inhibition of lactate dehydrogenase. The in vitro effects of chloroquine were identified at the end of the 1960s. The growth of many different viruses in cell cultures is inhibited by both chloroquine and hydroxychloroquine. These include the SARS coronavirus. Studies with experimental animals have offered a variety of evidence about the human coronavirus OC43, enterovirus EV-A71, Zika virus and influenza A H5N1. However, a
randomized, double-blind placebo-controlled clinical study by Paton et al.\textsuperscript{10} provided evidence that chloroquine did not affect influenza virus infection. An in vitro study of the Chikungunya virus reported a promising antiviral activity.\textsuperscript{11} However, in vivo studies showed that chloroquine increased alpha virus replication due to immune modulation and anti-inflammatory properties.\textsuperscript{12} In addition to all of this, these two medications are used for treatment of autoimmune situations like systemic lupus erythematosus and rheumatoid arthritis.\textsuperscript{13} Hydroxychloroquine and chloroquine accumulate in lysosomes of phagocytic cells and auto phagosomes and change local pH concentrations and may inhibit important cellular functions and molecular pathways affecting immune activation (MHC class II expression inhibition, antigen presentation, reduction of CD 154 by T cells, inhibition of production of a variety of proinflammatory cytokines like IL-2, IFNα, and TNF protecting against cytokine-mediated cartilage absorption, effect on toll-like receptor 7 (TLR7) and TLR9 signal pathways, interaction with cAMP and cGMP activity).\textsuperscript{14} Chloroquine analogs are weak diprotic bases. They may infiltrate organelles like endosomes and lysosomes. This situation prevents endosome leak and viral fusion with the cell. This mechanism leads to consideration that these medications may be effective for treatment of COVID-19. Additionally, research has revealed that these medications intervene in SARS-CoV-2 receptor binding and glycosylation of ACE-2 receptors preventing subsequent infection. In vitro studies in recent times reported that chloroquine and hydroxychloroquine at MOI: 0.01 ratio had effective dose interval of 2.71 µM and 4.51µM at 50% effective concentration for VERO-E6 cells in SARS-CoV-2 infection. At all MOI (0.01, 0.02, 0.2 and 0.8), the EC50 for chloroquine is lower than for hydroxychloroquine.\textsuperscript{15} A study identified that hydroxychloroquine is more effective for SARS-CoV-2 infection compared to chloroquine. In this study, hydroxychloroquine sulfate was given twice on the first day at 400 mg dose and then twice at 200 mg dose for the following 4 days.\textsuperscript{16} In a double-blind, randomized phase IIb study in Brazil, high-dose chloroquine (600 mg twice per day for 10 days for 41 patient) and low-dose chloroquine (twice per day on the first day and once per day for the following 4 days in 40 patient) were administered in 81 patients carrying SARS-CoV-2 virus and admitted to hospital with severe acute respiratory distress syndrome. In these patients, the mortality rate was lower in the group given high-dose chloroquine compared to the low-dose group. The researchers have concluded that when oseltamivir and azithromycin are administered simultaneously, administration of high-dose chloroquine to COVID-19 patients is not recommended as it is not safe. In fact, age is an important factor.\textsuperscript{17} Chloroquine is a medication which is administered in oral form. For COVID-19 treatment, the recommended dose is 500 mg tablet form given twice per day for 10 days.\textsuperscript{18} Bioavailability is close to complete with oral intake. Chloroquine is metabolized to the active metabolite of diacetyl chloroquine. This is mediated by CYP2C8 and CYP3A4. Chloroquine is the major substrate of CYP2D6. This enzyme comprises nearly 30% of inactivation.\textsuperscript{19} Chloroquine is eliminated in urine. Creatine clearance above 10 mL/min does not require dose adjustment. The side effects of chloroquine and hydroxychloroquine are usually mild and temporary. The most commonly observed side effects are those linked to gastrointestinal
intolerance. These include nausea, vomiting, abdominal cramps, and metallic taste in the mouth. Retinopathy may be observed with high-dose for a long period. Both chloroquine and hydroxychloroquine have minimal risk in pregnancy. These agents are accepted as safe. However, the limit between therapeutic and toxic doses is narrow and chloroquine intoxication may cause life-threatening cardiovascular disorders. Though rare, people with heart disease and lengthened QTc should avoid use due to torsades de pointes. To minimize cardiac adverse effects, administration should be avoided with medications that lengthen QTc and CYP2D6 inhibitors. As a result, there should be definite rules for the use of these medications, and self-treatment is not recommended. This is important especially in elderly patients with heart disease receiving cardiotoxic medications. Phase IV studies reported hypoglycemia advancing to loss of consciousness when these medications were administered after antidiabetic medications in patients with diabetes. As a result, an important element is routine monitoring of patients receiving chloroquine treatment with blood sugar and electrocardiogram tests due to QTc interval and hypoglycemia. Due to reduced chelation potential and bioavailability, chloroquine administration should be avoided within 4 hours of antacid administration. There is an interaction between proton pump inhibitors (PPI) and chloroquine analogs. PPI may block H+ and K+ ATPase in lysosomes and elevate pH and reduce medication accumulation which may weaken immunomodulatory effects. However, the in vivo effects of this interaction are unknown. These medications need to be better researched with clinical studies of COVID-19 cases.

**Remdesivir**

Remdesivir (GS-5734) is a nucleotide analog preliminary medication metabolized in the cell to an adenosine triphosphate analog inhibiting viral RNA polymerases. Remdesivir has a broad-spectrum effect against members of many virus families including filoviruses and coronaviruses. In vivo and in vitro studies have shown prophylactic and therapeutic efficacy. In the deadly murine model of MERS, remdesivir was proven to be superior to combined interferon beta and lopinavir-ritonavir regime. Remdesivir is a strong inhibitor of SARS-CoV-2 replication in the epithelial cells of the human nose and bronchial airway. A study by Jonathan et al. administered remdesivir treatment of 200 mg intravenous on the 1st day and then 100 mg for 9 days for patients admitted with COVID-19 diagnosis with disease due to SARS-CoV-2 infection. They identified 68% improvement. However, the researchers stated there was a need for randomized placebo-controlled studies to measure the efficacy of the medication. The potential mechanisms for remdesivir in COVID-19 are still uncertain. A variety of theories have been proposed in order to interpret the effect of remdesivir. The first of these is that though remdesivir does not disrupt exoribonuclease activity, it may affect nsp 12 polymerase. Additionally, remdesivir may effectively produce active nucleoside triphosphate (NTP) acting pharmacologically as an RNA chain terminator and alternative substrate. NTP active triphosphates are included in viral RNA inhibiting coronaviruses. There is a high genetic barrier for coronavirus to be able to develop resistance against remdesivir. This situation leads to the consideration that remdesivir may preserve its efficacy for coronavirus treatment without resistance.
Experimental studies have observed that therapeutic remdesivir (administered 2 hours after infection) inhibited SARS-CoV-2 replication but did not show prophylactic effect in timed tests using Vero-6 cells. Clinical studies in the USA reported that a patient exposed to COVID-19 infection improved after remdesivir administration. Another clinical research identified 68% improvement in 53 patients with severe COVID-19. The evidence presented in experimental studies and clinical research lead to the conclusion that remdesivir may be effective for COVID-19 treatment. However, there are insufficient randomized, controlled studies to assess the efficacy and safety of remdesivir in COVID-19 cases. As a result, there is a need for more randomized and controlled studies to be performed. Hence, it appears that the benefit-harm ratio of remdesivir in COVID-19 treatment has still not been fully explained. Remdesivir was proven to inhibit coronavirus in in vivo and in vitro studies. It was identified to improve reduced respiratory functions due to coronavirus effects both prophylactically and therapeutically. However, it would be wrong to say anything definite in COVID-19 cases because there is an insufficient amount of evidence.

Favipiravir

Favipiravir (T-705; 6-fluoro-3-hydroxy-2-pyrazinecarboxamide) is a new antiviral compound selectively and strongly inhibiting RNA polymerase linked to RNA in influenza and many other RNA viruses. Favipiravir is phosphorybosylated to the active form of favipiravir-ribofuranosyl-5'-triphosphate (RTP) by cellular enzymes. The antiviral effect occurs when viral RNA polymerase mistakenly identifies favipiravir-RTP as purine nucleotide and weakens with the addition of purine nucleic acids. It was shown to inhibit all influenza A, B, and C serotypes and strains. Additionally, both in vivo and in vitro models have shown an effect against a range of arenavirus, bunyavirus and flavivirus. Strong in vitro activity was shown against alphavirus, paramyxovirus and norovirus families.

A study with healthy Japanese volunteers related to the pharmacokinetics of favipiravir showed that maximum plasma concentrations were reached 2 hours after oral administration and then reduced with a short half-life of 2-2.5 hours. Favipiravir had a 54% binding rate to plasma proteins. The binding percentages for favipiravir to human serum albumin and α1-acid glycoprotein are 65% and 6.5%, respectively. The main medication metabolism occurs in the liver mediated by aldehyde oxidase and partly by xanthine oxidase. The inactive oxidative metabolite of T-705-M1 is excreted by the kidneys.

Dose selection is critical for antiviral purposes. The IC50 of favipiravir displays variations from nanomolar to micromolar concentrations in viral studies. Clinical research in Japan stated the permitted favipiravir regime for influenza was 3200 mg oral loading dose on the 1st day (1600 mg every 12 hours) and then 600 mg on the 2nd and 5th days. A higher dose regime (1800 mg twice on 1st day, then 800 mg twice per day) is accepted in phase III. This regime has proven efficacy and safety for influenza. Adverse reactions include mild and moderate severity diarrhea, asymptomatic increase in blood uric acid and transaminases, and reduction in neutrophil count. A study in China used favipiravir for COVID-19 treatment and showed 3200 mg on the 1st day (1600 mg twice per day) as loading dose, then 1200 mg maintenance dose on
the 2nd and 14th days (600 mg twice per day) was effective.36

When investigated from a pharmacokinetic aspect, in vitro studies of favipiravir showed it was potent on selective estrogen receptor blockers, H2 receptor antagonists, cimetidine calcium channel blockers, the antiarrhythmic medication of propafenone and tricyclic antidepressant amitriptyline AO receptors.37 Though there is no clinical information based on AO inhibition, obvious DDI was reported between cimetidine and zaleplon.38 Interactions between these medications and favipiravir should be carefully monitored.39

The use of favipiravir may be mentioned for COVID-19. However, there is still a need for more clinical research in order to interpret the definite efficacy of favipiravir. Potential interactions linked to AO inhibition should not be ignored.

**Lopinavir-Ritonavir**

Lopinavir-ritonavir were previously known as protease inhibitors intervening in the replication and synthesis of the HIV causing the production of non-infectious virus particles. As a result of the molecular model assessment, lopinavir and ritonavir were reported to be able to bind to the endopeptidase C30 in the SARS-CoV-2 protease. This situation led to the consideration that lopinavir and ritonavir may show antiviral effects by inhibiting SARS-CoV-2 protein synthesis. Additionally, there is evidence that the use of lopinavir/ritonavir (LPV/RTV) alone or in combination with other antiviral medications improves severe ARDS developing linked to SARS and MERS.39,40 It was considered that LPV/RTV may be effective in treatment of COVID-19 infection considering the similarity of SARS-CoV-2 to this virus.41 Lopinavir is a sensitive substrate for cytochrome P450 3A4 (CYP3A4) and p-glycoprotein and binds to protein in plasma at high rates (98-99%). Absorption occurs at stomach pH linked to intestinal CYP3A4 expression and P-glycoprotein activity. Hepatic and intestinal CYP3A4 expression contributes to systemic clearance of lopinavir. Ritonavir binds to protein at high rates. It is a substrate of CYP3A4 and to a lesser extent CYP2D6 and P-glycoprotein.42 Clinical drug-drug interaction studies have shown that LPV/RTV inhibits CYP3A4 and CYP2D6, and induces CYP2C9, CYP2C19 and CYP1A2.43 LPV/RTV has shown potential to both inhibit and induce UDP glucuronosyl transferase. When administered together, LPV/RTV was shown to have drug interactions mediated by drug-metabolizing enzymes, in addition to drug-carrier mediated interactions. As an example, when LPV/RTV are administered together, plasma rosuvastatin and pravastatin concentrations contain solute carrier organic anion transporter 1B1 (SLCO1B1) and ATP-binding cassette subfamily G member 2 (ABCG2)/ Breast cancer resistance protein (BCRP) carriers.44,45 As a result, it is necessary to be careful of drug-drug interactions when using LPV/RTV for SARS-CoV-2 infections.

**Nitazoxanide**

Nitazoxanide and the active metabolite tizoxanide were shown to have strong in vitro activity against SARS-CoV-2 and MERS-CoV in Vero E6 cells. Nitazoxanide increases cytoplasmic RNA perception and type I IFN pathways regulating natural antiviral mechanisms. Due to broad-spectrum antiviral activity, it was trialed in randomized controlled clinical studies for treatment of influenza and other acute respiratory tracts. However, results
have still not gained certainty in terms of clinical use.\textsuperscript{13} Nitazoxanide is suitable for intake with food. In plasma, tizoxanide binds to proteins at 99% rates. Nitazoxanide was not studied in patients with renal and liver failure. As a result, no recommendations are known about dose setting. There is no data available for geriatric and pediatric groups. Adverse effects of abdominal pain, nausea and headache are most common. Apart from this, patients may have color changes in eyes and urine, diarrhea, dizziness, skin rash, and gastroesophageal reflux.\textsuperscript{46,19} Nitazoxanide is not metabolized by CYP540 enzymes. As a result, interaction with other drugs does not occur by this route. As nitazoxanide binds to proteins at high rates, interaction with other drugs may be in the form of competition for binding sites with other drugs binding to proteins at high rates.\textsuperscript{19}

**Nelfinavir**

Nelfinavir mesylate was developed as an anti-human immunodeficiency virus (HIV) protease inhibitor. Apart from this, cell culture studies have reported nelfinavir inhibits SARS replication and cytopathic effects. In addition to strong activity against HIV protease, it was observed to have multiple effects on cellular processes including apoptosis and necrosis and inducing cell-protective mechanisms.\textsuperscript{37} During the SARS epidemic emerging in 2002, nelfinavir was identified as a potential agent with activity against SARS-CoV infection. Effects against SARS-CoV-2 and SARS-CoV were not researched in humans. The recommended dose for HIV treatment is 750 mg 3 times per day by the oral route or 1250 mg twice per day.\textsuperscript{19} Nelfinavir is metabolized by CYP3A4 and CYP2A19. As a result, it may interact with drugs metabolized by these enzymes. Nelfinavir may cause gastrointestinal intolerance.\textsuperscript{48}

**Oseltamivir**

Neuraminidase inhibitors are expected to reduce influenza complications in people at high risk in terms of influenza complications. Additionally, one of the most unsettling aspects of oseltamivir use is severe sudden death, and oseltamivir is reported to have severe neuropsychiatric adverse reactions including neuropsychiatric behavior causing accidental death. Since 2007 in Japan, it is contraindicated in children from 10-19 years due to risk of abnormal behavior.\textsuperscript{49} Studies about oseltamivir for COVID-19 treatment continue. However, a study in Wuhan city reported that no positive outcomes were observed after antiviral treatment administered with oseltamivir.\textsuperscript{50} Oseltamivir, favipiravir and chloroquine are used in a variety of combinations. Some clinical research has added oseltamivir. However, a review by Sander et al. reported that oseltamivir has no benefit for COVID-19 treatment after influenza is excluded.\textsuperscript{51}

**Tocilizumab**

Tocilizumab is an FDA-approved monoclonal antibody for chimeric antigen receptor T cell-derived cytokine release syndrome, giant cell arteritis, rheumatoid arthritis, and polyarticular and juvenile idiopathic arthritis.\textsuperscript{19} Data show that lung damage develops linked to inflammatory cytokine fluctuations in COVID-19 patients and, as a result, a cytokine storm forms. As a result of viral replication, hyperinflammation and further lung damage, the immune system is activated to release a variety of signal proteins like IL. IL-6 is an important inflammatory protein on this pathway. Tocilizumab binding to IL-6 recep-
tors blunts the cell signal and effectively downregulates the excessive immune response. In patients infected with SARS virus, cytokine release syndrome (CRS) was identified as a result of the release of proinflammatory markers containing IL-6 and TNF α. In MERS patients, IL-6, IL-8 and IL 1 β elevations were discovered. In severe COVID-19 patients in Wuhan city, high cytokine levels were recorded including IL-6 and granulocyte stimulating factors. Data recorded in Wuhan stated that in severe COVID-19 patients, tocilizumab added to lopinavir, methylprednisolone, and oxygen treatment caused rapid falls in fever, 75% rate of improvement in oxygenation and 95% of patients were discharged from hospital. For many indications, the dose of tocilizumab is 800 mg/kg. The dose for use in COVID-19 treatment still remains uncertain. Additionally, a study used a dose of 400 mg/kg. Tocilizumab should be carefully assessed in terms of adverse effects. Patients should be assessed for active or latent tuberculosis before administering tocilizumab. After tocilizumab use, gastrointestinal perforation was reported in patients with diverticulitis history or receiving high-dose corticosteroids.

There may be drug-drug interactions with tocilizumab linked to increased CYP540 activity. In vivo studies reported that tocilizumab may enter interaction with simvastatin linked to increased CYP3A4 activity. Similarly, it may enter interaction with omeprazole linked to CYP19 activity. Tocilizumab should be carefully assessed in terms of adverse effects. Patients should be assessed for active or latent tuberculosis before administering tocilizumab.

For many indications, the dose of tocilizumab is 800 mg/kg. The dose for use in COVID-19 treatment still remains uncertain. Additionally, a study used a dose of 400 mg/kg. Tocilizumab should be carefully assessed in terms of adverse effects. Patients should be assessed for active or latent tuberculosis before administering tocilizumab.

Corticosteroids

The purpose of corticosteroid use in COVID-19 patients is to reduce the inflammatory response causing acute lung damage and acute respiratory distress syndrome. This benefit may severely suppress delayed viral clearance and increase secondary infection risk. Observational studies in SARS and MERS patients did not offer any findings related to improved survival. However, it may be associated with delayed viral clearance in respiratory tract and blood and high rates of complications like hyperglycemia, avascular necrosis and psychosis. Additionally, a meta-analysis of 10 observational studies including 6548 patients showed that corticosteroids increased mortality risk and had 2 times higher secondary infection risk. Another retrospective study found no benefit from 300

Corticosteroids

The purpose of corticosteroid use in COVID-19 patients is to reduce the inflammatory response causing acute lung damage and acute respiratory distress syndrome. This benefit may severely suppress delayed viral clearance and increase secondary infection risk. Observational studies in SARS and MERS patients did not offer any findings related to improved survival. However, it may be associated with delayed viral clearance in respiratory tract and blood and high rates of complications like hyperglycemia, avascular necrosis and psychosis. Additionally, a meta-analysis of 10 observational studies including 6548 patients showed that corticosteroids increased mortality risk and had 2 times higher secondary infection risk. Another retrospective study found no benefit from 300
mg hydrocortisone per day in critical MERS patients for 90-day mortality; however, they found viral clearance was delayed in these patients. A study in recent times administered corticosteroids to 11 of 31 COVID-19 patients. Regression analysis found no correlation between corticosteroid intake with virus clearance duration and hospital stay. However, an interesting finding is that 2 patients with hepatitis B infection had slower virus clearance duration in this study. In this situation, corticosteroids may be considered if required for alternative indications like only septic shock or bronchoconstriction. They should be avoided in routine use.

**Azithromycin**

Azithromycin was shown to be an active agent in vitro against the Ebola virus. Apart from this, azithromycin has good potential to prevent severe respiratory tract infections in preschool children. It is administered to patients affected by viral infections. According to a study, 500 mg on the 1st day and 250 mg azithromycin on days 2-5 significantly strengthened the efficacy of hydroxychloroquine. However, a study by Borba et al. administered high dose and low dose chloroquine to 81 adult patients. They observed the death rate with high-dose chloroquine was reduced by 50%. However, the researchers did not recommend high-dose chloroquine administered simultaneously to oseltamivir and azithromycin especially due to safety dangers. There are no other clinical studies related to the use of azithromycin for COVID-19. The reason for the very few studies showing viral efficacy of azithromycin is that it is a classic antibiotic and has unknown effects on SARS-CoV-2 infection.

**Vaccinations**

The whole world is united in facing the COVID-19 pandemic. In this war, health workers and researchers around the world are struggling against the SARS-CoV-2 threat. Researchers are performing record levels of studies to find a vaccine against this virus. Approaches to vaccine development include classic inactivated and weakened vaccines, protein subunit and virus-like particle vaccines, viral vector-based vaccines, and DNA- and RNA-based vaccines. Each approach has its own specific advantages and disadvantages. However, all approaches should be developed at the same time in order to find an effective vaccine.

Among structured proteins on the virus, the spike protein is the most promising for vaccine development. This vaccine development is common for all coronaviruses and ensures the formation of an immune response by exposing an individual’s immune system and recalling this response for protection in the future. Additionally, this vaccination should prevent entry of the virus into susceptible cells and prevent infection.

As of December 11, 2020, fifty-eight vaccine candidates are currently conducting the clinical trial phase. Forty of these are at Phase I-II and 18 of them are at Phase III-IV. No vaccine candidates have yet completed Phase III. Prominent of these vaccines include Pfizer-BioNTech (MRna), Moderna (MRna), CanSino (Adenovirüs), Gamaleya (Adenovirüs), Johnson&Johnson (Adenovirüs), Oxford-AstraZeneca (Adenovirüs), Novovax (Protein), Vektör Enstitüsü (Protein), Sinopharm-Pekin (Inaktive), Sinopharm-Wuhan
Inactivated, Sinovac (Inakive). It is to be hoped that all studies will achieve success in the shortest time.

CONCLUSION

The COVID-19 pandemic is a very large global pandemic. The world was unprepared for this pandemic which required acceleration of pharmaceutical industry studies and research to develop new treatments targeting SARS-CoV-2 infection. This process may be beneficial for COVID-19 patients and scientists working in all areas of medical science continue to attempt a variety of treatments in the name of struggling with this virus. Though this review may be encouraging in terms of treatment with some agents, the side effects linked to the use of medications beneficial for treatment may be severe and evidence is still not definite. The evidence related to COVID-19 treatment is changing nearly every day. However, there is a need for more information about medications used or that can be used for COVID-19 treatment. Knowing the pharmacodynamic and pharmacokinetic properties of medications will lead to smarter structuring of treatment. The treatment process should be individualized according to the patient and disease progression.

At the moment, there is no vaccine and/or treatment strategies available for full treatment or protection from SARS-CoV-2. Additionally, it does not appear possible to finalize these within 3-12 months. As a result, public health strategies effective against this continuing pandemic are required. Among these strategies are early case identification and isolation, contact tracing of potential secondary cases, limitation of close contact, travel limitations, social isolation, hygiene and regular handwashing.

If the required conditions are met, the virus reproduction count will drop and transmission rate will reduce. These precautions are temporary to gain time while vaccine and medication development studies continue.

REFERENCES


Hama R. The mechanisms of delayed onset type adverse reactions to oseltamivir. Infect Dis 2016;48(9):651-660.


64. Coronavirus disease (COVID-19) Vaccines. https://www.who.int/news-room/q-a-detail/coronavirus-disease-(covid-19)-vaccines?adgroupsurvey={adgroupsurvey}&gclid=EAIaIQobChMI87j0sJWN7wIvrQWiAx1dYQxIAAYASAAEglJvD_BwE. Access Date: 19.02.2021